Company news: Amylin, Eli Lilly, Alkermes, Gilead and J&J

Share this article:

Amylin, Eli Lilly and Alkermes said the FDA accepted their Bydureon resubmission and awarded a six-month review, extending the PDUFA date to January 28, 2012. The response, which follows two 2010 rejections, likely includes a recently completed tQT study, DURATION-5 study and an integrated safety update. In a recent note, Collins Stewart analyst Salveen Richter pointed out that in the UK, where the once-weekly type 2 diabetes treatment was approved in June, Bydureon has been priced below fellow GLP-1 drug Victoza, “potentially due to or to partially offset DURATION-6 headwinds,” in which Bydureon failed a non-inferiority test vs. the Novo Nordisk drug. “We remain cautious on the commercial viability of Bydureon.”

The FDA approved a one-pill, once-daily combination of Gilead's Truvada and Johnson & Johnson's Edurant HIV meds. Analysts anticipate that the pill, to be marketed as Complera, will achieve broad first-line use, despite having lower efficacy among sicker patients than the market leader, Gilead/BMS's combo pill Atripla, which had 2010 US sales of $2.2 billion, according to Wolters Kluwer Pharma Solutions wholesale acquisition cost data. Truvada, which is also an antiviral cocktail in a pill, garnered $1.69 billion in US sales.

Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.